Use of HPV vaccine in men should be considered to prevent development of HPV related anal cancers. A
a single‐arm, open‐label, multicenter clinical trial was performed to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV‐1–infected men.
Men with high‐grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination.
Results showed that vaccine was well tolerated, and showed successful seroconversion: for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV‐1 RNA levels were observed.
Conclusions.
The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV‐1–infected men. Efficacy studies in HIV‐1–infected men, especially in preventing anal cancer, are warranted.
The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV‐1–infected men. Efficacy studies in HIV‐1–infected men, especially in preventing anal cancer, are warranted. http://www.journals.uchicago.edu/doi/abs/10.1086/656320
No comments:
Post a Comment